asapiprant
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2012 (NCT01651871)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Prostanoid DP receptorANTAGONIST
PTGDR antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)Oc1ccc(S(=O)(=O)N2CCN(c3ccc(-c4ncco4)c(OCC(=O)O)c3)CC2)cc1- Mol. weight
- 501.56 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545043 ↗
Also known as
- asapiprant
- asapiprant
- s-555739
- s-555739
- s-555739
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01651871 | Phase 2 | Jul 1, 2012 | Shionogi |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shionogi | For profit | 1 | 1 | 1 | 2012 |
1 organizations
Page 1 / 1